9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria

Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria

Urinary tract infections (UTIs) represent one of the most prevalent bacterial infections encountered across primary care, urgent care, and long-term care settings. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), board certification demands precision in differentiating uncomplicated from complicated UTIs, adhering to strict antimicrobial stewardship guidelines (especially avoiding overtreatment of asymptomatic bacteriuria), implementing evidence-based therapies for recurrent UTIs in postmenopausal women, managing acute pyelonephritis, and executing rigorous diagnostic evaluations for microscopic hematuria in accordance with American Urological Association (AUA) risk-stratification guidelines.

---

1. Microbiology & Pathogenesis of Urinary Tract Infections

Primary Uropathogens Across Clinical Settings

+-----------------------------------------------------------------------------+
|                        SPECTRUM OF UROPATHOGENS                             |
|                                                                             |
|   1. UROPATHOGENIC ESCHERICHIA COLI (UPEC)                                  |
|      - Responsible for 75% to 95% of acute uncomplicated cystitis and       |
|        pyelonephritis; ~50% of complicated/hospital-acquired UTIs.          |
|      - Virulence factors: Type 1 fimbriae (mannose-sensitive; bind bladder  |
|        uroplakin), P-fimbriae (Gal-Gal binding; ascends to renal parenchyma)|
|                                                                             |
|   2. STAPHYLOCOCCUS SAPROPHYTICUS                                           |
|      - Coagulase-negative, Novobiocin-resistant Gram-positive coccus.       |
|      - 5% to 15% of acute cystitis in young, sexually active females.        |
|                                                                             |
|   3. KLEBSIELLA PNEUMONIAE & ENTEROBACTER SPECIES                           |
|      - Gram-negative bacilli; frequent in diabetics and complicated UTIs.   |
|                                                                             |
|   4. PROTEUS MIRABILIS                                                      |
|      - Urease-producing Gram-negative rod (hydrolyzes urea to NH3 + CO2).   |
|      - Produces alkaline urine (pH > 7.5), driving precipitation of         |
|        magnesium ammonium phosphate -> STRUVITE (STAGHORN) CALCULI.         |
|                                                                             |
|   5. ENTEROCOCCUS FAECALIS & ENTEROCOCCUS FAECIUM                           |
|      - Gram-positive cocci in pairs/chains; common in elderly men, post-    |
|        instrumentation, catheter-associated UTIs (CAUTI).                   |
|                                                                             |
|   6. PSEUDOMONAS AERUGINOSA                                                 |
|      - Non-fermenting Gram-negative bacillus; common in chronic indwelling  |
|        catheters, neurogenic bladder, urinary stents, and post-urologic sx. |
+-----------------------------------------------------------------------------+

---

2. Clinical Classification & Diagnostic Evaluation

+-----------------------------------------------------------------------------+
|                   CLINICAL CLASSIFICATION OF URINARY TRACT INFECTIONS       |
|                                                                             |
|   [ ASYMPTOMATIC BACTERIURIA ]      [ ACUTE UNCOMPLICATED CYSTITIS ]        |
|   - Growth >= 10^5 CFU/mL in        - Dysuria, frequency, urgency, suprapub |
|     asymptomatic patient.             pain in healthy non-pregnant female.  |
|   - DO NOT TREAT (Except pregnancy  - No fever, no flank pain, normal tract.|
|     and invasive urologic surgery!).- Empiric 1st-line Rx without culture.  |
|                                                                             |
|   [ COMPLICATED UTI ]               [ ACUTE PYELONEPHRITIS ]                |
|   - UTI in MEN, pregnancy, poorly   - Upper tract infection: Fever, chills, |
|     controlled DM, immunosuppressed,  nausea/vomiting, CVA tenderness.      |
|     catheter (CAUTI), anatomic/     - Urinalysis hallmark: WBC CASTS.       |
|     functional obstruction, CKD.    - Urine & blood cultures MANDATORY.     |
|   - Urine culture MANDATORY.        - Extended 7-14 day targeted therapy.   |
+-----------------------------------------------------------------------------+

Urinalysis Interpretation: Chemical Dipstick & Microscopic Analysis

1. Leukocyte Esterase (LE): Enzyme produced by lysed neutrophils reflecting pyuria. Sensitivity 75–95%, specificity 65–95% for UTI. ($> 5\text{--}10\text{ WBCs/HPF}$ on microscopy confirms pyuria).
2. Nitrites: Gram-negative enterobacteriaceae (E. coli, Klebsiella, Proteus) reduce dietary nitrates into nitrites.
   • High Specificity ($>95%$): A positive nitrite strongly confirms enterobacteriaceae presence.
   • Low Sensitivity (~50%): A negative nitrite does not rule out infection! False negatives occur with: Gram-positive uropathogens (Enterococcus, Staphylococcus saprophyticus), Pseudomonas, low dietary vegetable intake, or frequent bladder emptying preventing the required 4-hour incubation period.
3. Urine Microscopy:
   • WBCs: $> 5\text{--}10\text{ WBCs/HPF}$ indicates pyuria/inflammation.
   • Epithelial Cells: $> 5\text{ squamous epithelial cells/HPF}$ indicates significant perineal contamination; specimen must be repeated with proper midstream clean-catch technique.
   • White Blood Cell (WBC) Casts: Cylindrical molds of polymorphonuclear leukocytes formed in the distal tubules and collecting ducts. Pathognomonic hallmark of Acute Pyelonephritis / Renal Parenchymal Inflammation, definitively distinguishing upper from lower tract infection.

Asymptomatic Bacteriuria (ASB): Strict Guidelines for Clinical Restraint

• Definition: Isolation of $\ge 10^5\text{ Colony-Forming Units (CFU)/mL}$ of a single uropathogen in a voided urine specimen in a patient without any signs or symptoms referable to a UTI (no dysuria, frequency, urgency, suprapubic pain, fever, or leukocytosis).
• Guideline-Directed Practice (IDSA / USPSTF): Screening and treating ASB provides no clinical benefit and increases adverse drug reactions, Clostridioides difficile colitis, and antimicrobial resistance in:
  • Premenopausal or postmenopausal non-pregnant women.
  • Diabetic individuals.
  • Elderly nursing home residents (pyuria + bacteriuria is present in $>30\text{--}50%$ of institutionalized elderly; treating asymptomatic foul-smelling or cloudy urine is malpractice!).
  • Patients with spinal cord injuries or neurogenic bladders.
  • Patients with indwelling urinary catheters.

+-----------------------------------------------------------------------------+
|             THE ONLY TWO STRICT INDICATIONS TO TREAT ASYMPTOMATIC           |
|                                 BACTERIURIA                                 |
|                                                                             |
|   1. PREGNANT INDIVIDUALS                                                   |
|      - Screen at 12 to 16 weeks gestation (or 1st prenatal visit).          |
|      - If positive (>= 10^5 CFU/mL), treat with 4-7 days of safe antibiotics |
|        (e.g., Cephalexin, Amoxicillin-Clavulanate, Nitrofurantoin [avoid     |
|        in 1st trimester and near term at 36-42 weeks]).                     |
|      - Rationale: Untreated ASB progresses to acute pyelonephritis in 20-40% |
|        of pregnancies, triggering preterm labor, sepsis, and low birth wt.  |
|                                                                             |
|   2. PATIENTS UNDERGOING INVASIVE UROLOGICAL SURGERY                        |
|      - Specifically procedures with anticipated mucosal trauma or bleeding  |
|        (e.g., Transurethral Resection of Prostate [TURP]).                  |
|      - Screen and treat prior to procedure to prevent bacteremia and sepsis.|
+-----------------------------------------------------------------------------+

---

3. Evidence-Based Antimicrobial Management

Acute Uncomplicated Cystitis (IDSA Guidelines)

In a non-pregnant, premenopausal female presenting with classic symptoms of lower cystitis without systemic features, empiric treatment without routine pre-treatment urine culture is appropriate.

[!WARNING] The Fluoroquinolone Black Box Warning Mandate: Fluoroquinolones (Ciprofloxacin, Levofloxacin, Ofloxacin) must NOT be prescribed for acute uncomplicated cystitis if other guideline-endorsed options are available. The FDA and IDSA issue severe warnings regarding disabling and potentially irreversible toxicities: tendonitis and tendon rupture (especially Achilles tendon), peripheral neuropathy, CNS toxicities (hallucinations, seizures), QT prolongation / torsades de pointes, aortic aneurysm rupture or dissection, and severe hypoglycemia. Reserve fluoroquinolones for acute pyelonephritis, complicated UTIs, and bacterial prostatitis.

Complicated Urinary Tract Infections (Including UTIs in Men)

• Diagnostic Mandate: A pre-treatment Urine Culture and Susceptibility test is mandatory for all complicated UTIs.
• UTI in Men: By definition, all UTIs in men are classified as complicated due to anatomical length, higher risk of structural obstruction (BPH, strictures), and potential prostatic parenchymal seeding.
• Treatment Duration: 7 to 14 days (longer durations required if prostatitis cannot be excluded):
  • Outpatient oral therapy: Ciprofloxacin $500\text{ mg}$ BID $\times 7\text{--}10\text{ days}$, Levofloxacin $750\text{ mg}$ daily $\times 5\text{--}7\text{ days}$, or TMP-SMX DS 1 tab BID $\times 10\text{--}14\text{ days}$ (adjusted based on culture results).

Acute Pyelonephritis Management Algorithm

+-----------------------------------------------------------------------------+
|                   ACUTE PYELONEPHRITIS DECISION ALGORITHM                   |
|                                                                             |
|                  [PATIENT WITH ACUTE PYELONEPHRITIS]                        |
|                  - Fever, Chills, Nausea, CVA Tenderness                    |
|                  - MANDATORY: Urine Culture + Blood Cultures                |
|                                      |                                      |
|                                      v                                      |
|               [EVALUATE CLINICAL SEVERITY & HOST FACTORS]                   |
|                                      |                                      |
|         +----------------------------+----------------------------+         |
|         |                                                         |         |
|         v                                                         v         |
|   [OUTPATIENT CANDIDATE]                                    [INPATIENT ADMISSION]   |
|   - Mild/moderate illness                                   - Sepsis / Shock        |
|   - Tolerating oral intake/meds                             - Intractable vomiting  |
|   - Reliable; compliant                                     - Pregnancy             |
|   - Normal anatomy/immunity                                 - Urinary obstruction   |
|                                                             - High fever / failed OP|
|         |                                                         |         |
|         v                                                         v         |
|   [ORAL ANTIMICROBIAL REGIMEN]                              [INTRAVENOUS THERAPY]   |
|   * Ciprofloxacin 500 mg BID x 7 d                          * IV Ceftriaxone 1-2g Q24H|
|   * Levofloxacin 750 mg daily x 5 d                         * IV Piperacillin-Tazo  |
|   * TMP-SMX DS BID x 14 d (if sens)                         * IV Cefepime / Meropenem|
|   (Note: If local FQ resistance >10%,                       - Step down to oral     |
|    administer initial dose of IV Ceftriaxone                  after 24-48 hr afebrile|
|    1g or Gentamicin in clinic first!).                      - Total: 10-14 days Rx. |
+-----------------------------------------------------------------------------+

---

4. Recurrent UTIs in Women: Diagnostic & Preventative Strategies

Diagnostic Definition

Recurrent UTI (rUTI) is formally defined as $\ge 2$ culture-proven episodes of acute uncomplicated cystitis within a 6-month period, OR $\ge 3$ culture-proven episodes within a 12-month period.

Pathophysiological Drivers in Postmenopausal Women

In postmenopausal women, estrogen depletion results in atrophy of the vaginal and vulvovaginal epithelium. The loss of glycogen leads to a collapse in the population of protective hydrogen-peroxide-producing Lactobacilli, causing vaginal pH to rise from an acidic normal ($ ext{pH } 3.8\text{--}4.5$) to an alkaline state ($ ext{pH} > 5.0\text{--}6.0$). This allows colonization of the vaginal introitus and periurethral area by pathogenic enteric coliforms (E. coli).

+-----------------------------------------------------------------------------+
|                 POSTMENOPAUSAL RECURRENT UTI PATHOPHYSIOLOGY                |
|                                                                             |
|                           [MENOPAUSE / ESTROGEN LOSS]                       |
|                                       |                                     |
|                                       v                                     |
|                        [Vaginal & Urethral Mucosal Atrophy]                 |
|                                       |                                     |
|                                       v                                     |
|                   [Depletion of Glycogen & Loss of Lactobacilli]            |
|                                       |                                     |
|                                       v                                     |
|                   [Vaginal pH Increases to Alkaline (> 5.5)]                |
|                                       |                                     |
|                                       v                                     |
|              [Enteric Coliform Colonization of Periurethral Space]          |
|                                       |                                     |
|                                       v                                     |
|                   [RECURRENT ASCENDING CYSTITIS & PYELONEPHRITIS]           |
+-----------------------------------------------------------------------------+

Evidence-Based Non-Antimicrobial & Pharmacological Management

1. Topical Vaginal Estrogen Therapy (First-Line in Postmenopausal Women):
   • Formulations: Vaginal Estradiol cream (0.5–1.0 g twice weekly), Estradiol vaginal ring (Estring), or Estradiol vaginal tablets (Vagifem 10 mcg twice weekly).
   • Mechanism: Re-establishes normal thick stratified squamous epithelium, restores glycogen production, promotes Lactobacilli recolonization, lowers vaginal pH to $<4.5$, and reduces recurrent UTI rates by 50% to 75%.
   • Systemic absorption is minimal; does not require concurrent progestin for endometrial protection.
2. Increased Hydration: Increasing daily water intake by $1.5\text{ Liters/day}$ in women with low baseline fluid intake reduces UTI recurrence by $\approx 50%$ via mechanical bladder flushing.
3. Post-Coital Voiding & Behavioral Habits: Voiding immediately after sexual intercourse; avoiding spermicidal contraceptives and diaphragms (which kill Lactobacilli).
4. Methenamine Hippurate ($1\text{ g}$ PO BID): Non-antibiotic urinary antiseptic hydrolyzed in acidic urine ($ ext{pH} < 5.5$) to form bactericidal formaldehyde; effective for non-antibiotic prophylaxis without generating resistance.
5. Antimicrobial Prophylaxis (Last Resort):
   • Post-Coital Single-Dose Prophylaxis: For sexually active women with coitus-related recurrences (e.g., TMP-SMX SS $80/400\text{ mg}$ or Nitrofurantoin $50\text{ mg}$ single oral dose immediately post-coitus).
   • Continuous Low-Dose Prophylaxis: Daily low-dose Nitrofurantoin $50\text{ mg}$ or TMP-SMX SS for 6 to 12 months in refractory cases.

---

5. Microscopic Hematuria: AUA / SUFU Risk Stratification & Diagnostic Workup

Diagnostic Definition of Microscopic Hematuria

According to the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) guidelines, Microhematuria is formally defined as:

$\mathbf{\ge 3\text{ Red Blood Cells per High-Power Field (RBCs/HPF)}}\text{ on microscopic evaluation of a properly collected, clean-catch urine specimen.}$

[!IMPORTANT] Dipstick Hematuria vs. Microscopic Examination: A positive chemical urine dipstick for blood (detecting heme via pseudoperoxidase activity) has high sensitivity ($>90%$) but poor specificity ($65\text{--}80%$) due to false positives from myoglobinuria, hemoglobinuria, povidone-iodine, or concentrated urine. A positive dipstick NEVER establishes the diagnosis of microhematuria. The AGPCNP must confirm the presence of $\ge 3\text{ RBCs/HPF}$ on formal microscopic urinalysis before initiating an invasive or radiologic hematuria evaluation!

Step 1: Exclude Benign / Transient Etiologies

Before initiating a full hematuria workup, evaluate and exclude reversible non-malignant triggers:

• Acute urinary tract infection (treat and repeat UA in 4–6 weeks to verify resolution).
• Menstrual contamination (repeat UA mid-cycle).
• Recent strenuous physical exercise / long-distance running (repeat UA in 2–3 weeks).
• Recent sexual intercourse or minor genitourinary trauma.
• Recent urological catheterization or instrumentation.

Step 2: Differentiate Glomerular vs. Non-Glomerular (Urological) Hematuria

+-----------------------------------------------------------------------------+
|                      URINE SEDIMENT CAST DIFFERENTIATION                    |
|                                                                             |
|   CAST TYPE               PATHOGNOMONIC CLINICAL ASSOCIATION                |
|   -----------------------------------------------------------------------   |
|   Red Blood Cell Casts    Acute Glomerulonephritis / Glomerular Hematuria   |
|   White Blood Cell Casts  Acute Pyelonephritis / Acute Interstitial Nephr.  |
|   Renal Tubular Cell Casts Acute Tubular Necrosis (ATN) / Ischemia / Toxins |
|   "Muddy Brown" Casts     Pathognomonic for Acute Tubular Necrosis (ATN)    |
|   Fatty Casts / Oval Fats Nephrotic Syndrome ("Maltese Cross" polarized)   |
|   Broad, Waxy Casts       Advanced Chronic Kidney Disease / ESRD            |
|   Hyaline Casts           Benign / Dehydration / Strenuous Exercise         |
+-----------------------------------------------------------------------------+

Step 3: AUA Risk Stratification for Microhematuria & Guideline-Directed Evaluation

For patients with confirmed non-glomerular microhematuria ($\ge 3\text{ RBCs/HPF}$), risk-stratify for urothelial malignancy:

+-----------------------------------------------------------------------------+
|                 AUA RISK STRATIFICATION FOR MICROHEMATURIA                  |
|                                                                             |
|   LOW RISK                                                                  |
|   - Women < 50 yrs, Men < 40 yrs                                            |
|   - Never smoker or < 10 pack-years                                         |
|   - 3 to 10 RBCs/HPF on microscopy                                          |
|   - No additional risk factors                                              |
|   ---> CLINICAL ACTION: Shared decision-making: Repeat UA in 6 months OR    |
|        Renal Ultrasound + Cystoscopy.                                       |
|                                                                             |
|   INTERMEDIATE RISK                                                         |
|   - Women 50-59 yrs, Men 40-59 yrs                                          |
|   - Smoking: 10 to 30 pack-years                                            |
|   - 11 to 25 RBCs/HPF on microscopy                                         |
|   ---> CLINICAL ACTION: RENAL ULTRASOUND + CYSTOSCOPY.                      |
|                                                                             |
|   HIGH RISK                                                                 |
|   - Women or Men >= 60 yrs                                                  |
|   - Smoking: > 30 pack-years                                                |
|   - > 25 RBCs/HPF on microscopy                                             |
|   - History of GROSS HEMATURIA                                              |
|   - High-Risk Features: Occupational exposure to aromatic amines/dyes,      |
|     prior pelvic radiation, cyclophosphamide exposure, indwelling catheter. |
|   ---> CLINICAL ACTION: MULTIPHASIC CT UROGRAPHY (CTU) + CYSTOSCOPY.        |
+-----------------------------------------------------------------------------+

• Multiphasic CT Urography (CTU): Gold-standard imaging modality for high-risk patients. Consists of: (1) Non-contrast phase (detects stones), (2) Nephrographic phase (detects renal parenchymal masses/RCC), and (3) Excretory delayed phase (opacifies renal pelvis, ureters, and bladder to identify filling defects and urothelial carcinoma).
• Cystoscopy: Mandatory gold standard to directly inspect the bladder urothelium and urethra; cross-sectional imaging cannot reliably exclude flat or small bladder mucosal lesions (carcinoma in situ).